Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)
Sponsor: Spinogenix
Summary
This phase 2 study will evaluate the safety, tolerability, clinical efficacy, pharmacokinetics, and pharmacodynamics of SPG302 in adult participants with mild-to-moderate AD.
Official title: A Phase 2, Randomized, Placebo-controlled, Double-Blind Multicenter Study to Assess the Safety, Tolerability, and Pharmacodynamics (PD) in Adult Participants With Mild-to Moderate Alzheimer's Disease (AD) Administered SPG302
Key Details
Gender
All
Age Range
45 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
24
Start Date
2024-07-29
Completion Date
2026-06
Last Updated
2025-08-17
Healthy Volunteers
No
Conditions
Interventions
SPG302
synthetic small molecule
Placebo
Placebo
Locations (2)
St Vincent's Hospital
Sydney, New South Wales, Australia
Flinders Medical center
Adelaide, South Australia, Australia